| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Particulate Matter | 66 | 2021 | 2523 | 5.980 |
Why?
|
| Air Pollution | 57 | 2021 | 2284 | 5.590 |
Why?
|
| Air Pollutants | 57 | 2021 | 2814 | 4.670 |
Why?
|
| Environmental Exposure | 50 | 2021 | 4231 | 4.140 |
Why?
|
| Myocardial Infarction | 96 | 2022 | 11690 | 3.650 |
Why?
|
| Vehicle Emissions | 20 | 2021 | 665 | 3.530 |
Why?
|
| Anger | 9 | 2016 | 402 | 2.520 |
Why?
|
| Alcohol Drinking | 32 | 2020 | 3957 | 2.490 |
Why?
|
| Cross-Over Studies | 52 | 2019 | 2030 | 1.870 |
Why?
|
| Stroke | 28 | 2023 | 9963 | 1.780 |
Why?
|
| Accidents, Occupational | 13 | 2015 | 251 | 1.620 |
Why?
|
| Weather | 8 | 2020 | 228 | 1.610 |
Why?
|
| Migraine Disorders | 12 | 2023 | 1620 | 1.580 |
Why?
|
| Alcoholic Beverages | 6 | 2020 | 265 | 1.520 |
Why?
|
| Cardiovascular Diseases | 54 | 2023 | 15108 | 1.430 |
Why?
|
| Coffee | 8 | 2015 | 578 | 1.400 |
Why?
|
| Middle Aged | 289 | 2023 | 213127 | 1.390 |
Why?
|
| Physical Exertion | 9 | 2018 | 695 | 1.380 |
Why?
|
| Hand Injuries | 8 | 2007 | 242 | 1.370 |
Why?
|
| Heart Failure | 35 | 2022 | 10856 | 1.370 |
Why?
|
| Marijuana Smoking | 5 | 2020 | 252 | 1.320 |
Why?
|
| Inhalation Exposure | 6 | 2017 | 443 | 1.260 |
Why?
|
| Headache | 6 | 2023 | 1219 | 1.250 |
Why?
|
| Ozone | 14 | 2019 | 469 | 1.250 |
Why?
|
| Risk Factors | 175 | 2022 | 72145 | 1.240 |
Why?
|
| Male | 337 | 2023 | 349538 | 1.220 |
Why?
|
| Erectile Dysfunction | 11 | 2017 | 459 | 1.220 |
Why?
|
| Sweden | 31 | 2021 | 1343 | 1.200 |
Why?
|
| Female | 337 | 2023 | 379592 | 1.160 |
Why?
|
| Aged | 238 | 2021 | 162944 | 1.130 |
Why?
|
| Humans | 459 | 2024 | 742088 | 1.070 |
Why?
|
| Forced Expiratory Volume | 7 | 2019 | 1741 | 1.060 |
Why?
|
| Welding | 10 | 2017 | 89 | 1.030 |
Why?
|
| Heart Transplantation | 3 | 2023 | 3119 | 1.010 |
Why?
|
| Linear Models | 26 | 2020 | 5948 | 0.980 |
Why?
|
| Residence Characteristics | 12 | 2019 | 2049 | 0.980 |
Why?
|
| Brain Ischemia | 13 | 2015 | 3258 | 0.960 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2024 | 3239 | 0.950 |
Why?
|
| Proportional Hazards Models | 52 | 2021 | 12344 | 0.940 |
Why?
|
| Hyperemia | 2 | 2016 | 224 | 0.930 |
Why?
|
| Arrhythmias, Cardiac | 12 | 2020 | 2267 | 0.930 |
Why?
|
| Housing | 4 | 2017 | 663 | 0.930 |
Why?
|
| Time Factors | 66 | 2022 | 40054 | 0.910 |
Why?
|
| Incidence | 55 | 2022 | 20928 | 0.910 |
Why?
|
| Cohort Studies | 77 | 2023 | 40450 | 0.890 |
Why?
|
| Adult | 183 | 2023 | 213712 | 0.860 |
Why?
|
| Temperature | 9 | 2019 | 2207 | 0.860 |
Why?
|
| Coronary Artery Bypass | 9 | 2009 | 2281 | 0.850 |
Why?
|
| Coronary Disease | 33 | 2009 | 6078 | 0.840 |
Why?
|
| Seasons | 8 | 2019 | 1492 | 0.840 |
Why?
|
| Heart Rate | 22 | 2017 | 4091 | 0.830 |
Why?
|
| Boston | 32 | 2021 | 9305 | 0.830 |
Why?
|
| Risk | 29 | 2019 | 9679 | 0.800 |
Why?
|
| Environmental Monitoring | 16 | 2021 | 1413 | 0.800 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2014 | 215 | 0.800 |
Why?
|
| Sleep | 12 | 2023 | 4604 | 0.790 |
Why?
|
| Sulfones | 5 | 2014 | 437 | 0.770 |
Why?
|
| Tea | 4 | 2007 | 275 | 0.770 |
Why?
|
| Prospective Studies | 90 | 2023 | 53187 | 0.760 |
Why?
|
| Epidemiologic Research Design | 5 | 2013 | 367 | 0.760 |
Why?
|
| Case-Control Studies | 42 | 2020 | 21719 | 0.760 |
Why?
|
| Risk Assessment | 48 | 2021 | 23320 | 0.750 |
Why?
|
| Caffeine | 4 | 2019 | 699 | 0.730 |
Why?
|
| Atherosclerosis | 5 | 2023 | 3428 | 0.730 |
Why?
|
| Anxiety | 7 | 2016 | 4279 | 0.730 |
Why?
|
| Occupational Exposure | 13 | 2017 | 1794 | 0.720 |
Why?
|
| Blood Pressure | 23 | 2022 | 8541 | 0.700 |
Why?
|
| Peripheral Arterial Disease | 8 | 2022 | 1184 | 0.700 |
Why?
|
| Cause of Death | 13 | 2015 | 3571 | 0.700 |
Why?
|
| Death, Sudden, Cardiac | 15 | 2014 | 1541 | 0.680 |
Why?
|
| United States | 74 | 2023 | 69693 | 0.680 |
Why?
|
| Stress, Psychological | 14 | 2023 | 4229 | 0.670 |
Why?
|
| Marijuana Abuse | 4 | 2022 | 402 | 0.670 |
Why?
|
| Needlestick Injuries | 4 | 2010 | 67 | 0.650 |
Why?
|
| Lung | 7 | 2020 | 9826 | 0.650 |
Why?
|
| Selection Bias | 2 | 2014 | 369 | 0.650 |
Why?
|
| Odds Ratio | 30 | 2020 | 9846 | 0.640 |
Why?
|
| Automobiles | 2 | 2016 | 116 | 0.640 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2018 | 46 | 0.640 |
Why?
|
| Piperazines | 5 | 2014 | 2488 | 0.640 |
Why?
|
| Inflammation | 13 | 2019 | 10578 | 0.640 |
Why?
|
| Aged, 80 and over | 89 | 2021 | 57683 | 0.630 |
Why?
|
| Cannabis | 2 | 2016 | 432 | 0.630 |
Why?
|
| Blood Pressure Determination | 5 | 2020 | 632 | 0.620 |
Why?
|
| Hospitalization | 27 | 2022 | 10232 | 0.600 |
Why?
|
| Research Subjects | 1 | 2019 | 238 | 0.590 |
Why?
|
| Hypercholesterolemia | 4 | 2015 | 1149 | 0.590 |
Why?
|
| Exercise | 16 | 2023 | 5611 | 0.580 |
Why?
|
| Diet | 13 | 2019 | 7923 | 0.580 |
Why?
|
| Occupational Diseases | 6 | 2007 | 1472 | 0.570 |
Why?
|
| Fishes | 2 | 2010 | 569 | 0.560 |
Why?
|
| Seafood | 2 | 2010 | 384 | 0.560 |
Why?
|
| Defibrillators, Implantable | 13 | 2015 | 1440 | 0.550 |
Why?
|
| Oxidative Stress | 2 | 2018 | 3081 | 0.550 |
Why?
|
| Sleep Deprivation | 2 | 2020 | 830 | 0.550 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 733 | 0.550 |
Why?
|
| Brachial Artery | 3 | 2014 | 370 | 0.550 |
Why?
|
| Confidence Intervals | 17 | 2015 | 2970 | 0.550 |
Why?
|
| Dinoprost | 1 | 2016 | 138 | 0.550 |
Why?
|
| Coronary Artery Disease | 14 | 2020 | 6454 | 0.540 |
Why?
|
| Logistic Models | 32 | 2022 | 13403 | 0.540 |
Why?
|
| Research Report | 1 | 2019 | 355 | 0.540 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2008 | 548 | 0.540 |
Why?
|
| Longitudinal Studies | 27 | 2021 | 13921 | 0.530 |
Why?
|
| Glomerular Filtration Rate | 3 | 2015 | 2167 | 0.530 |
Why?
|
| Adipokines | 1 | 2017 | 318 | 0.520 |
Why?
|
| Pulsatile Flow | 2 | 2016 | 332 | 0.520 |
Why?
|
| Carbon | 10 | 2019 | 686 | 0.520 |
Why?
|
| Dust | 2 | 2017 | 479 | 0.510 |
Why?
|
| Diabetes Mellitus | 10 | 2023 | 5724 | 0.510 |
Why?
|
| Tobacco Smoke Pollution | 5 | 2019 | 814 | 0.510 |
Why?
|
| Nature | 1 | 2014 | 15 | 0.500 |
Why?
|
| Air Pollutants, Occupational | 9 | 2017 | 408 | 0.490 |
Why?
|
| C-Reactive Protein | 12 | 2019 | 3766 | 0.490 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 807 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2014 | 1573 | 0.490 |
Why?
|
| Public Facilities | 1 | 2014 | 34 | 0.490 |
Why?
|
| Nitrogen Dioxide | 10 | 2021 | 490 | 0.480 |
Why?
|
| Abruptio Placentae | 3 | 2021 | 118 | 0.480 |
Why?
|
| Particle Size | 15 | 2017 | 1640 | 0.480 |
Why?
|
| Continuous Positive Airway Pressure | 6 | 2022 | 546 | 0.480 |
Why?
|
| Ethanol | 2 | 2016 | 1337 | 0.470 |
Why?
|
| Total Lung Capacity | 1 | 2013 | 143 | 0.460 |
Why?
|
| Prevalence | 27 | 2022 | 15194 | 0.460 |
Why?
|
| Disease Progression | 12 | 2020 | 13256 | 0.460 |
Why?
|
| Military Personnel | 1 | 2022 | 1132 | 0.460 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 4147 | 0.460 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 391 | 0.450 |
Why?
|
| Follow-Up Studies | 48 | 2021 | 39004 | 0.450 |
Why?
|
| Massachusetts | 17 | 2019 | 8662 | 0.450 |
Why?
|
| Environment | 4 | 2014 | 1115 | 0.440 |
Why?
|
| Tachycardia, Ventricular | 10 | 2019 | 1272 | 0.440 |
Why?
|
| Peroxidase | 1 | 2016 | 610 | 0.440 |
Why?
|
| Sleep Apnea Syndromes | 5 | 2022 | 941 | 0.440 |
Why?
|
| Fingers | 1 | 2016 | 514 | 0.440 |
Why?
|
| Prognosis | 34 | 2022 | 29010 | 0.430 |
Why?
|
| Dilatation, Pathologic | 1 | 2014 | 520 | 0.430 |
Why?
|
| Multivariate Analysis | 23 | 2019 | 12242 | 0.430 |
Why?
|
| Influenza, Human | 1 | 2023 | 1472 | 0.420 |
Why?
|
| Inflammation Mediators | 3 | 2017 | 1889 | 0.420 |
Why?
|
| Myocardial Ischemia | 8 | 2009 | 2145 | 0.420 |
Why?
|
| Diabetic Angiopathies | 5 | 2005 | 820 | 0.420 |
Why?
|
| Drinking Behavior | 3 | 2011 | 103 | 0.410 |
Why?
|
| Kidney Diseases | 2 | 2017 | 2145 | 0.410 |
Why?
|
| Hypertension | 16 | 2022 | 8455 | 0.410 |
Why?
|
| Widowhood | 1 | 2012 | 54 | 0.410 |
Why?
|
| Ventricular Fibrillation | 7 | 2015 | 538 | 0.400 |
Why?
|
| Waist Circumference | 2 | 2013 | 917 | 0.400 |
Why?
|
| Microvessels | 1 | 2016 | 544 | 0.400 |
Why?
|
| Lacerations | 5 | 2015 | 144 | 0.400 |
Why?
|
| Fatty Liver | 1 | 2017 | 728 | 0.400 |
Why?
|
| Vasodilator Agents | 4 | 2005 | 976 | 0.390 |
Why?
|
| alpha-Linolenic Acid | 1 | 2011 | 144 | 0.390 |
Why?
|
| Obesity | 13 | 2016 | 12705 | 0.390 |
Why?
|
| Accidental Falls | 7 | 2015 | 1057 | 0.380 |
Why?
|
| Survival Analysis | 16 | 2021 | 10248 | 0.380 |
Why?
|
| Nutrition Surveys | 7 | 2017 | 1656 | 0.380 |
Why?
|
| Accidents, Traffic | 2 | 2012 | 819 | 0.380 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2023 | 199 | 0.380 |
Why?
|
| Linoleic Acid | 1 | 2011 | 157 | 0.380 |
Why?
|
| Humidity | 5 | 2015 | 197 | 0.370 |
Why?
|
| Age Factors | 20 | 2017 | 18355 | 0.360 |
Why?
|
| Heart | 9 | 2017 | 4462 | 0.360 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2010 | 1341 | 0.360 |
Why?
|
| Soot | 5 | 2018 | 232 | 0.360 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2021 | 2099 | 0.360 |
Why?
|
| Cross-Sectional Studies | 27 | 2020 | 24913 | 0.360 |
Why?
|
| Nitric Oxide | 2 | 2016 | 2128 | 0.350 |
Why?
|
| Electrocardiography, Ambulatory | 14 | 2016 | 585 | 0.350 |
Why?
|
| Fish Products | 1 | 2009 | 29 | 0.350 |
Why?
|
| Cacao | 1 | 2010 | 98 | 0.350 |
Why?
|
| Grief | 1 | 2012 | 247 | 0.350 |
Why?
|
| Greenhouse Effect | 1 | 2009 | 26 | 0.340 |
Why?
|
| Gloves, Protective | 2 | 2010 | 22 | 0.340 |
Why?
|
| Nitrogen Oxides | 4 | 2017 | 129 | 0.340 |
Why?
|
| Aorta | 1 | 2017 | 2057 | 0.340 |
Why?
|
| Personnel, Hospital | 3 | 2010 | 283 | 0.330 |
Why?
|
| Sulfur Dioxide | 7 | 2019 | 177 | 0.330 |
Why?
|
| Ventricular Premature Complexes | 2 | 2023 | 111 | 0.330 |
Why?
|
| West Nile virus | 1 | 2009 | 79 | 0.330 |
Why?
|
| Kidney Transplantation | 3 | 2022 | 4246 | 0.330 |
Why?
|
| West Nile Fever | 1 | 2009 | 78 | 0.330 |
Why?
|
| Plant Preparations | 1 | 2009 | 94 | 0.330 |
Why?
|
| Angina Pectoris | 10 | 2008 | 977 | 0.330 |
Why?
|
| Sleep Apnea, Obstructive | 5 | 2022 | 1808 | 0.320 |
Why?
|
| Fluorides | 2 | 2006 | 126 | 0.320 |
Why?
|
| Occupations | 4 | 2020 | 517 | 0.320 |
Why?
|
| Live Birth | 1 | 2012 | 512 | 0.320 |
Why?
|
| Calcinosis | 1 | 2017 | 1497 | 0.310 |
Why?
|
| Wounds and Injuries | 5 | 2014 | 2400 | 0.310 |
Why?
|
| Dietary Supplements | 4 | 2014 | 3294 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 4 | 2015 | 2714 | 0.310 |
Why?
|
| Sulfates | 4 | 2017 | 390 | 0.310 |
Why?
|
| Meat-Packing Industry | 3 | 2015 | 12 | 0.310 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2012 | 501 | 0.300 |
Why?
|
| Circadian Rhythm | 9 | 2010 | 2623 | 0.300 |
Why?
|
| Blood Glucose | 8 | 2020 | 6249 | 0.300 |
Why?
|
| Motor Activity | 4 | 2013 | 2714 | 0.300 |
Why?
|
| Metals | 3 | 2016 | 717 | 0.300 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 802 | 0.290 |
Why?
|
| Educational Status | 8 | 2019 | 2533 | 0.290 |
Why?
|
| Registries | 15 | 2021 | 8077 | 0.290 |
Why?
|
| Autonomic Nervous System | 6 | 2017 | 671 | 0.290 |
Why?
|
| Wit and Humor as Topic | 1 | 2006 | 31 | 0.290 |
Why?
|
| Research Design | 6 | 2014 | 5979 | 0.290 |
Why?
|
| Cholesterol | 7 | 2009 | 2895 | 0.290 |
Why?
|
| Nutrition Assessment | 2 | 2009 | 723 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 2 | 2005 | 204 | 0.280 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2015 | 2407 | 0.280 |
Why?
|
| Occupational Health | 5 | 2004 | 809 | 0.280 |
Why?
|
| Life Change Events | 1 | 2012 | 937 | 0.280 |
Why?
|
| Fluoridation | 1 | 2006 | 29 | 0.280 |
Why?
|
| Motor Vehicles | 3 | 2016 | 268 | 0.280 |
Why?
|
| Arthritis | 1 | 2012 | 658 | 0.280 |
Why?
|
| Mortality | 9 | 2021 | 2857 | 0.280 |
Why?
|
| Carbon Monoxide | 7 | 2019 | 531 | 0.280 |
Why?
|
| Endothelial Cells | 2 | 2018 | 3455 | 0.280 |
Why?
|
| Glycemic Index | 4 | 2010 | 395 | 0.280 |
Why?
|
| Ischemia | 6 | 2022 | 1911 | 0.280 |
Why?
|
| Glucose | 2 | 2017 | 4391 | 0.270 |
Why?
|
| Pulmonary Emphysema | 3 | 2020 | 672 | 0.270 |
Why?
|
| Retrospective Studies | 37 | 2023 | 77098 | 0.270 |
Why?
|
| Platelet Count | 1 | 2008 | 780 | 0.270 |
Why?
|
| Emotions | 6 | 2016 | 2657 | 0.270 |
Why?
|
| Acute Coronary Syndrome | 4 | 2014 | 2337 | 0.270 |
Why?
|
| Epidemiologic Methods | 5 | 2010 | 1364 | 0.270 |
Why?
|
| Feeding Behavior | 5 | 2017 | 3187 | 0.260 |
Why?
|
| Leukocyte Count | 2 | 2008 | 1583 | 0.260 |
Why?
|
| Endovascular Procedures | 4 | 2022 | 1973 | 0.260 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2021 | 997 | 0.260 |
Why?
|
| Politics | 2 | 2023 | 790 | 0.260 |
Why?
|
| Health Status | 3 | 2019 | 4030 | 0.250 |
Why?
|
| Smoking | 17 | 2019 | 8969 | 0.250 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 460 | 0.250 |
Why?
|
| Allied Health Personnel | 2 | 2003 | 162 | 0.250 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2021 | 3526 | 0.250 |
Why?
|
| Nonlinear Dynamics | 4 | 2019 | 502 | 0.250 |
Why?
|
| Causality | 7 | 2015 | 1265 | 0.250 |
Why?
|
| Risk Reduction Behavior | 4 | 2019 | 1123 | 0.250 |
Why?
|
| Young Adult | 30 | 2023 | 56350 | 0.250 |
Why?
|
| Aspirin | 7 | 2014 | 3278 | 0.250 |
Why?
|
| Models, Statistical | 11 | 2019 | 5100 | 0.250 |
Why?
|
| Cardiovascular System | 2 | 2013 | 827 | 0.240 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 1224 | 0.240 |
Why?
|
| Adiposity | 2 | 2016 | 1806 | 0.240 |
Why?
|
| Ventricular Function, Left | 3 | 2018 | 3656 | 0.240 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 683 | 0.240 |
Why?
|
| Fibrinogen | 12 | 2019 | 894 | 0.240 |
Why?
|
| Impotence, Vasculogenic | 1 | 2003 | 11 | 0.240 |
Why?
|
| New England | 5 | 2007 | 1021 | 0.240 |
Why?
|
| Coronary Angiography | 12 | 2016 | 4567 | 0.240 |
Why?
|
| Lead | 1 | 2009 | 854 | 0.230 |
Why?
|
| Diet Surveys | 7 | 2017 | 1172 | 0.230 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 1148 | 0.230 |
Why?
|
| Restaurants | 3 | 2010 | 236 | 0.230 |
Why?
|
| Trauma Severity Indices | 2 | 2002 | 481 | 0.230 |
Why?
|
| Breast Feeding | 2 | 2009 | 1339 | 0.230 |
Why?
|
| Physicians | 2 | 2019 | 4554 | 0.230 |
Why?
|
| Survival Rate | 13 | 2012 | 12773 | 0.230 |
Why?
|
| Saphenous Vein | 1 | 2006 | 531 | 0.230 |
Why?
|
| Beverages | 2 | 2019 | 820 | 0.220 |
Why?
|
| Mexican Americans | 1 | 2004 | 166 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 3 | 2021 | 1527 | 0.220 |
Why?
|
| Sternotomy | 2 | 2021 | 121 | 0.220 |
Why?
|
| Interviews as Topic | 8 | 2010 | 2536 | 0.220 |
Why?
|
| United States Environmental Protection Agency | 4 | 2019 | 139 | 0.220 |
Why?
|
| Sex Factors | 9 | 2015 | 10392 | 0.220 |
Why?
|
| Alcoholic Intoxication | 1 | 2004 | 188 | 0.220 |
Why?
|
| Hypolipidemic Agents | 2 | 2008 | 604 | 0.220 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2020 | 1538 | 0.210 |
Why?
|
| Hemoglobins | 1 | 2008 | 1532 | 0.210 |
Why?
|
| Nicotine | 2 | 2019 | 677 | 0.210 |
Why?
|
| Atrial Fibrillation | 7 | 2017 | 5019 | 0.210 |
Why?
|
| Actigraphy | 3 | 2023 | 488 | 0.210 |
Why?
|
| Women's Health | 2 | 2011 | 2034 | 0.210 |
Why?
|
| Insulin Resistance | 4 | 2020 | 3861 | 0.210 |
Why?
|
| Antithrombins | 2 | 2019 | 304 | 0.210 |
Why?
|
| Survivors | 3 | 2018 | 2286 | 0.210 |
Why?
|
| Workplace | 2 | 2010 | 836 | 0.210 |
Why?
|
| DNA Methylation | 6 | 2019 | 4282 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2021 | 3336 | 0.210 |
Why?
|
| Thailand | 1 | 2022 | 296 | 0.200 |
Why?
|
| Dietary Fats | 1 | 2010 | 2017 | 0.200 |
Why?
|
| Antilymphocyte Serum | 1 | 2023 | 491 | 0.200 |
Why?
|
| Vascular Surgical Procedures | 4 | 2020 | 1473 | 0.200 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2001 | 67 | 0.200 |
Why?
|
| Depression | 7 | 2021 | 7733 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 4414 | 0.200 |
Why?
|
| Nursing Homes | 3 | 2015 | 1034 | 0.200 |
Why?
|
| Hockey | 1 | 2002 | 90 | 0.190 |
Why?
|
| Acute Disease | 9 | 2022 | 7141 | 0.190 |
Why?
|
| Lipids | 6 | 2023 | 3302 | 0.190 |
Why?
|
| Chi-Square Distribution | 9 | 2017 | 3510 | 0.190 |
Why?
|
| Rhabdomyolysis | 2 | 2019 | 150 | 0.190 |
Why?
|
| Birth Weight | 2 | 2009 | 2068 | 0.190 |
Why?
|
| Health Surveys | 5 | 2019 | 4030 | 0.190 |
Why?
|
| Urban Health | 4 | 2017 | 547 | 0.190 |
Why?
|
| Arabs | 1 | 2023 | 177 | 0.190 |
Why?
|
| Insulin | 3 | 2013 | 6575 | 0.190 |
Why?
|
| Socioeconomic Factors | 10 | 2019 | 7770 | 0.190 |
Why?
|
| Drug Interactions | 4 | 2019 | 1458 | 0.190 |
Why?
|
| Respiratory Function Tests | 3 | 2020 | 1613 | 0.190 |
Why?
|
| Cold Temperature | 2 | 2015 | 774 | 0.190 |
Why?
|
| Medicare | 6 | 2021 | 6532 | 0.190 |
Why?
|
| Alcohol-Induced Disorders | 1 | 2020 | 26 | 0.180 |
Why?
|
| Osteosarcoma | 1 | 2006 | 880 | 0.180 |
Why?
|
| Adolescent | 29 | 2023 | 85649 | 0.180 |
Why?
|
| Allostasis | 1 | 2021 | 70 | 0.180 |
Why?
|
| Skiing | 2 | 2000 | 24 | 0.180 |
Why?
|
| Comorbidity | 14 | 2021 | 10372 | 0.180 |
Why?
|
| Tachycardia | 3 | 2016 | 620 | 0.180 |
Why?
|
| Angioscopy | 5 | 2003 | 49 | 0.180 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2020 | 54 | 0.180 |
Why?
|
| Breath Tests | 2 | 2016 | 276 | 0.180 |
Why?
|
| Fibrinolysis | 6 | 2002 | 322 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 10943 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 783 | 0.180 |
Why?
|
| Body Mass Index | 14 | 2019 | 12695 | 0.180 |
Why?
|
| Diabetes Complications | 4 | 2003 | 1359 | 0.180 |
Why?
|
| Vital Capacity | 3 | 2019 | 922 | 0.180 |
Why?
|
| Income | 2 | 2019 | 1904 | 0.180 |
Why?
|
| Air Pollution, Indoor | 4 | 2013 | 855 | 0.170 |
Why?
|
| Cholesterol, HDL | 6 | 2013 | 1813 | 0.170 |
Why?
|
| Predictive Value of Tests | 13 | 2020 | 15056 | 0.170 |
Why?
|
| Regression Analysis | 10 | 2020 | 6452 | 0.170 |
Why?
|
| Stroke Volume | 6 | 2018 | 4983 | 0.170 |
Why?
|
| Fatigue | 1 | 2006 | 1526 | 0.170 |
Why?
|
| Attitude to Health | 2 | 2008 | 2051 | 0.170 |
Why?
|
| Purines | 4 | 2008 | 593 | 0.170 |
Why?
|
| Sex Characteristics | 2 | 2009 | 2585 | 0.170 |
Why?
|
| Marriage | 1 | 2000 | 338 | 0.170 |
Why?
|
| Infant, Premature | 1 | 2008 | 2041 | 0.170 |
Why?
|
| Intergenerational Relations | 1 | 2019 | 68 | 0.170 |
Why?
|
| Aging | 9 | 2014 | 8626 | 0.170 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 551 | 0.160 |
Why?
|
| Thrombosis | 2 | 2012 | 2966 | 0.160 |
Why?
|
| Hemostasis | 6 | 2005 | 458 | 0.160 |
Why?
|
| Coronary Thrombosis | 5 | 2003 | 494 | 0.160 |
Why?
|
| Spirometry | 3 | 2019 | 862 | 0.160 |
Why?
|
| Health Behavior | 7 | 2019 | 2630 | 0.160 |
Why?
|
| Waist-Hip Ratio | 3 | 2009 | 517 | 0.160 |
Why?
|
| Creatinine | 3 | 2016 | 1916 | 0.160 |
Why?
|
| American Heart Association | 3 | 2013 | 1055 | 0.160 |
Why?
|
| Infant, Low Birth Weight | 1 | 2023 | 850 | 0.160 |
Why?
|
| British Columbia | 4 | 2012 | 241 | 0.160 |
Why?
|
| Task Performance and Analysis | 2 | 2009 | 780 | 0.160 |
Why?
|
| Cardiopulmonary Bypass | 4 | 2019 | 1066 | 0.160 |
Why?
|
| Motivation | 1 | 2008 | 1968 | 0.160 |
Why?
|
| Body Height | 2 | 2001 | 1574 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2019 | 416 | 0.150 |
Why?
|
| Interleukin-6 | 5 | 2019 | 3199 | 0.150 |
Why?
|
| Monte Carlo Method | 2 | 2015 | 1254 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 3611 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 793 | 0.150 |
Why?
|
| Violence | 1 | 2004 | 908 | 0.150 |
Why?
|
| Pregnancy | 14 | 2021 | 29087 | 0.150 |
Why?
|
| Cardiovascular Agents | 4 | 2008 | 848 | 0.150 |
Why?
|
| Platelet Aggregation | 4 | 2005 | 800 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 3151 | 0.150 |
Why?
|
| Antioxidants | 3 | 2017 | 1659 | 0.150 |
Why?
|
| Lovastatin | 2 | 2008 | 120 | 0.150 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 15530 | 0.150 |
Why?
|
| Hospital Mortality | 5 | 2018 | 5310 | 0.140 |
Why?
|
| Physical Fitness | 3 | 2015 | 732 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 2 | 2001 | 643 | 0.140 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2020 | 279 | 0.140 |
Why?
|
| Manometry | 2 | 2016 | 444 | 0.140 |
Why?
|
| Urban Population | 5 | 2013 | 2018 | 0.140 |
Why?
|
| Sleep Stages | 2 | 2017 | 686 | 0.140 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2017 | 453 | 0.140 |
Why?
|
| Lipoprotein(a) | 3 | 2013 | 425 | 0.140 |
Why?
|
| Automobile Driving | 3 | 2009 | 431 | 0.140 |
Why?
|
| Homocysteine | 2 | 2014 | 647 | 0.140 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 2024 | 0.140 |
Why?
|
| Aerosols | 1 | 2018 | 623 | 0.140 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1035 | 0.140 |
Why?
|
| Vascular Grafting | 1 | 2017 | 142 | 0.140 |
Why?
|
| Rifamycins | 1 | 2015 | 25 | 0.140 |
Why?
|
| Lactulose | 1 | 2015 | 33 | 0.140 |
Why?
|
| Shoes | 3 | 2010 | 98 | 0.130 |
Why?
|
| Analysis of Variance | 5 | 2010 | 6365 | 0.130 |
Why?
|
| Mountaineering | 1 | 1995 | 45 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2009 | 3695 | 0.130 |
Why?
|
| Placebos | 2 | 2019 | 1677 | 0.130 |
Why?
|
| Probability | 3 | 2018 | 2502 | 0.130 |
Why?
|
| Age of Onset | 4 | 2008 | 3266 | 0.130 |
Why?
|
| Sensitivity and Specificity | 14 | 2012 | 14720 | 0.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 485 | 0.130 |
Why?
|
| Chest Pain | 1 | 2002 | 1113 | 0.130 |
Why?
|
| Family | 2 | 2019 | 3144 | 0.130 |
Why?
|
| Atrophy | 2 | 2015 | 1576 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2017 | 357 | 0.130 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 1864 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2014 | 11695 | 0.130 |
Why?
|
| Hand Strength | 1 | 2018 | 444 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 7 | 2005 | 281 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2021 | 20086 | 0.130 |
Why?
|
| Gestational Age | 2 | 2015 | 3490 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 994 | 0.130 |
Why?
|
| Postoperative Period | 4 | 2020 | 1839 | 0.130 |
Why?
|
| Mercury | 1 | 2017 | 285 | 0.120 |
Why?
|
| Electric Countershock | 4 | 2007 | 535 | 0.120 |
Why?
|
| Hyperlipidemias | 3 | 2006 | 786 | 0.120 |
Why?
|
| Stress, Physiological | 2 | 2000 | 1402 | 0.120 |
Why?
|
| Cerebral Infarction | 2 | 2015 | 1007 | 0.120 |
Why?
|
| Nutritive Value | 1 | 2017 | 339 | 0.120 |
Why?
|
| Software | 2 | 2024 | 4434 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2013 | 3067 | 0.120 |
Why?
|
| Denmark | 4 | 2018 | 736 | 0.120 |
Why?
|
| Hepatic Encephalopathy | 1 | 2015 | 139 | 0.120 |
Why?
|
| Social Environment | 1 | 2019 | 1023 | 0.120 |
Why?
|
| beta-Glucans | 1 | 2015 | 123 | 0.120 |
Why?
|
| Electrocardiography | 10 | 2017 | 6440 | 0.120 |
Why?
|
| Floors and Floorcoverings | 2 | 2010 | 26 | 0.120 |
Why?
|
| Oxidants, Photochemical | 2 | 2011 | 78 | 0.120 |
Why?
|
| Betaine | 1 | 2014 | 81 | 0.120 |
Why?
|
| Kidney | 2 | 2009 | 7167 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2005 | 2643 | 0.120 |
Why?
|
| Primary Prevention | 4 | 2015 | 1166 | 0.120 |
Why?
|
| Personality Inventory | 2 | 2013 | 1026 | 0.120 |
Why?
|
| Anticonvulsants | 2 | 2015 | 1914 | 0.120 |
Why?
|
| Heparin | 1 | 2021 | 1636 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2522 | 0.120 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 3058 | 0.120 |
Why?
|
| Students, Medical | 1 | 2006 | 1858 | 0.120 |
Why?
|
| Arousal | 1 | 2019 | 1165 | 0.120 |
Why?
|
| Rage | 1 | 2013 | 30 | 0.120 |
Why?
|
| Cocaine | 1 | 1999 | 1008 | 0.110 |
Why?
|
| Interview, Psychological | 2 | 2013 | 812 | 0.110 |
Why?
|
| Telephone | 1 | 1997 | 617 | 0.110 |
Why?
|
| Dietary Carbohydrates | 2 | 2010 | 904 | 0.110 |
Why?
|
| Monitoring, Intraoperative | 2 | 2019 | 953 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2020 | 3038 | 0.110 |
Why?
|
| Pulmonary Veins | 1 | 2019 | 759 | 0.110 |
Why?
|
| Zalcitabine | 1 | 2012 | 42 | 0.110 |
Why?
|
| Patient Compliance | 4 | 2019 | 2680 | 0.110 |
Why?
|
| Matched-Pair Analysis | 2 | 2005 | 288 | 0.110 |
Why?
|
| Angina, Unstable | 5 | 2009 | 926 | 0.110 |
Why?
|
| Preoperative Period | 3 | 2020 | 546 | 0.110 |
Why?
|
| Simvastatin | 1 | 2015 | 360 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 759 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2013 | 1239 | 0.110 |
Why?
|
| Epidemiology | 1 | 2015 | 287 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1178 | 0.110 |
Why?
|
| Endotoxins | 1 | 2015 | 525 | 0.110 |
Why?
|
| Food Handling | 2 | 2010 | 145 | 0.110 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2014 | 194 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 7 | 2009 | 1873 | 0.110 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 3639 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2017 | 1517 | 0.110 |
Why?
|
| Choline | 1 | 2014 | 487 | 0.110 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2013 | 135 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2019 | 1317 | 0.110 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2014 | 245 | 0.110 |
Why?
|
| Movement | 1 | 2019 | 1470 | 0.110 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 325 | 0.110 |
Why?
|
| Treatment Outcome | 21 | 2022 | 62966 | 0.100 |
Why?
|
| Electronic Health Records | 2 | 2019 | 4440 | 0.100 |
Why?
|
| Life Style | 7 | 2009 | 3824 | 0.100 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 316 | 0.100 |
Why?
|
| Sex Distribution | 3 | 2011 | 2295 | 0.100 |
Why?
|
| Lower Extremity | 2 | 2017 | 1151 | 0.100 |
Why?
|
| Social Isolation | 3 | 2006 | 363 | 0.100 |
Why?
|
| Fruit | 2 | 2014 | 1139 | 0.100 |
Why?
|
| Ticlopidine | 1 | 2017 | 899 | 0.100 |
Why?
|
| Rain | 2 | 2009 | 61 | 0.100 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 288 | 0.100 |
Why?
|
| Graft Survival | 1 | 2022 | 3733 | 0.100 |
Why?
|
| Vegetables | 2 | 2014 | 1179 | 0.100 |
Why?
|
| Markov Chains | 1 | 2015 | 969 | 0.100 |
Why?
|
| Peritoneal Dialysis | 2 | 2002 | 146 | 0.100 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2372 | 0.100 |
Why?
|
| Coffea | 1 | 2011 | 22 | 0.100 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 591 | 0.100 |
Why?
|
| Vaccination | 1 | 2023 | 3256 | 0.100 |
Why?
|
| Age Distribution | 5 | 2011 | 2900 | 0.100 |
Why?
|
| Ventricular Pressure | 1 | 2012 | 199 | 0.100 |
Why?
|
| Patient Readmission | 2 | 2015 | 3111 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2013 | 367 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1794 | 0.100 |
Why?
|
| Heart Diseases | 4 | 2014 | 2789 | 0.100 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2011 | 97 | 0.100 |
Why?
|
| Food-Processing Industry | 1 | 2010 | 15 | 0.100 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 135 | 0.100 |
Why?
|
| Meat | 2 | 2012 | 595 | 0.100 |
Why?
|
| Triglycerides | 3 | 2013 | 2450 | 0.100 |
Why?
|
| Creatine Kinase | 3 | 2003 | 694 | 0.090 |
Why?
|
| Polysomnography | 4 | 2019 | 1772 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2015 | 494 | 0.090 |
Why?
|
| Cholecalciferol | 1 | 2015 | 537 | 0.090 |
Why?
|
| Nuclear Family | 1 | 2012 | 318 | 0.090 |
Why?
|
| Bicycling | 1 | 2012 | 176 | 0.090 |
Why?
|
| Zidovudine | 1 | 2012 | 620 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2019 | 1911 | 0.090 |
Why?
|
| Hemodynamics | 3 | 2013 | 4197 | 0.090 |
Why?
|
| Fructose | 1 | 2012 | 288 | 0.090 |
Why?
|
| Weight Lifting | 1 | 2010 | 131 | 0.090 |
Why?
|
| Protective Clothing | 1 | 2010 | 102 | 0.090 |
Why?
|
| Parity | 2 | 2011 | 929 | 0.090 |
Why?
|
| North Carolina | 1 | 2010 | 311 | 0.090 |
Why?
|
| Heart Conduction System | 3 | 2009 | 1048 | 0.090 |
Why?
|
| Hot Temperature | 2 | 2013 | 1355 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 1423 | 0.090 |
Why?
|
| Social Class | 1 | 2019 | 1995 | 0.090 |
Why?
|
| Epigenomics | 1 | 2015 | 902 | 0.090 |
Why?
|
| Population Surveillance | 4 | 2009 | 2616 | 0.090 |
Why?
|
| Communication | 1 | 2024 | 3728 | 0.090 |
Why?
|
| Social Support | 5 | 2006 | 2117 | 0.090 |
Why?
|
| Reproducibility of Results | 8 | 2015 | 19862 | 0.090 |
Why?
|
| Brain | 4 | 2016 | 26343 | 0.090 |
Why?
|
| Mississippi | 2 | 2020 | 89 | 0.090 |
Why?
|
| Placenta | 1 | 2019 | 1694 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2017 | 848 | 0.090 |
Why?
|
| Microcirculation | 1 | 2014 | 1285 | 0.090 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 542 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2015 | 722 | 0.090 |
Why?
|
| Vasodilation | 1 | 2014 | 944 | 0.090 |
Why?
|
| Adiponectin | 2 | 2013 | 1099 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2014 | 5095 | 0.090 |
Why?
|
| Smoke | 2 | 2009 | 226 | 0.090 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4455 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2019 | 2572 | 0.090 |
Why?
|
| Incineration | 1 | 2009 | 20 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.090 |
Why?
|
| Benzodiazepines | 1 | 2015 | 1101 | 0.090 |
Why?
|
| Air Pressure | 1 | 2009 | 75 | 0.090 |
Why?
|
| Protective Devices | 1 | 2009 | 71 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 1499 | 0.090 |
Why?
|
| Algorithms | 8 | 2019 | 13853 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2022 | 4393 | 0.080 |
Why?
|
| Nebraska | 3 | 2015 | 35 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2011 | 595 | 0.080 |
Why?
|
| Poverty Areas | 2 | 2013 | 273 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 7 | 2004 | 1262 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 115 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2000 | 187 | 0.080 |
Why?
|
| Tai Ji | 1 | 2012 | 284 | 0.080 |
Why?
|
| World Health Organization | 2 | 2013 | 1317 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2019 | 3493 | 0.080 |
Why?
|
| Glutathione | 1 | 2011 | 586 | 0.080 |
Why?
|
| Myostatin | 1 | 2009 | 124 | 0.080 |
Why?
|
| Child | 11 | 2022 | 77478 | 0.080 |
Why?
|
| Insect Vectors | 1 | 2009 | 134 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 1181 | 0.080 |
Why?
|
| California | 2 | 2020 | 1400 | 0.080 |
Why?
|
| CpG Islands | 3 | 2019 | 1170 | 0.080 |
Why?
|
| Finland | 2 | 2019 | 602 | 0.080 |
Why?
|
| Databases, Factual | 4 | 2020 | 7716 | 0.080 |
Why?
|
| Anesthesia | 1 | 2019 | 1548 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 1384 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 379 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2017 | 4211 | 0.080 |
Why?
|
| Maternal Exposure | 1 | 2015 | 961 | 0.080 |
Why?
|
| Marital Status | 1 | 2009 | 437 | 0.080 |
Why?
|
| Propensity Score | 3 | 2021 | 1771 | 0.080 |
Why?
|
| Coronary Vessels | 4 | 2003 | 3099 | 0.080 |
Why?
|
| Thallium Radioisotopes | 2 | 1999 | 139 | 0.080 |
Why?
|
| Mathematics | 1 | 2009 | 727 | 0.080 |
Why?
|
| Men's Health | 1 | 2008 | 73 | 0.080 |
Why?
|
| Dioxins | 1 | 2008 | 102 | 0.080 |
Why?
|
| Coronary Circulation | 2 | 2012 | 1572 | 0.080 |
Why?
|
| New York City | 2 | 2021 | 706 | 0.080 |
Why?
|
| Dipyridamole | 2 | 1999 | 145 | 0.080 |
Why?
|
| Nutritional Requirements | 1 | 2009 | 285 | 0.080 |
Why?
|
| Arteries | 2 | 2014 | 1118 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2009 | 298 | 0.070 |
Why?
|
| Cleft Lip | 1 | 2012 | 476 | 0.070 |
Why?
|
| Wood | 1 | 2007 | 88 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2019 | 3461 | 0.070 |
Why?
|
| Angioplasty | 1 | 2009 | 364 | 0.070 |
Why?
|
| Lead Poisoning | 1 | 2009 | 304 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 970 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2012 | 558 | 0.070 |
Why?
|
| Homeostasis | 1 | 2017 | 3335 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 3 | 2014 | 1342 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2006 | 5774 | 0.070 |
Why?
|
| Safety Management | 3 | 2010 | 782 | 0.070 |
Why?
|
| Leptin | 1 | 2014 | 1593 | 0.070 |
Why?
|
| Self Medication | 1 | 2007 | 117 | 0.070 |
Why?
|
| Food | 1 | 2011 | 769 | 0.070 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2010 | 577 | 0.070 |
Why?
|
| Legionellosis | 1 | 2005 | 11 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2015 | 9941 | 0.070 |
Why?
|
| Postoperative Complications | 7 | 2021 | 15244 | 0.070 |
Why?
|
| Pennsylvania | 4 | 2009 | 613 | 0.070 |
Why?
|
| Panax | 1 | 2005 | 29 | 0.070 |
Why?
|
| Acceleration | 2 | 2017 | 181 | 0.070 |
Why?
|
| Nurses | 1 | 2015 | 2459 | 0.070 |
Why?
|
| Patient Discharge | 4 | 2017 | 3300 | 0.070 |
Why?
|
| Respiration Disorders | 1 | 2009 | 370 | 0.070 |
Why?
|
| Risk Management | 1 | 2009 | 571 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 1421 | 0.070 |
Why?
|
| Entropy | 2 | 2018 | 209 | 0.070 |
Why?
|
| Fires | 1 | 2007 | 173 | 0.070 |
Why?
|
| Infertility, Female | 1 | 2011 | 784 | 0.070 |
Why?
|
| Hypotension | 1 | 2011 | 880 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2012 | 1320 | 0.070 |
Why?
|
| Canada | 2 | 2010 | 2061 | 0.070 |
Why?
|
| Asthma | 3 | 2018 | 5955 | 0.060 |
Why?
|
| Rest | 1 | 2010 | 900 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 2684 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 185 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2011 | 786 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2008 | 596 | 0.060 |
Why?
|
| von Willebrand Factor | 6 | 2009 | 668 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 2276 | 0.060 |
Why?
|
| Amitriptyline | 1 | 1984 | 110 | 0.060 |
Why?
|
| Poisson Distribution | 3 | 2012 | 512 | 0.060 |
Why?
|
| Ventricular Dysfunction | 1 | 2005 | 143 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 3915 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2023 | 1661 | 0.060 |
Why?
|
| Carbolines | 1 | 2006 | 265 | 0.060 |
Why?
|
| Cariostatic Agents | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cardiology | 1 | 2015 | 1658 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2004 | 191 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 1872 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 959 | 0.060 |
Why?
|
| Psychometrics | 1 | 2013 | 2999 | 0.060 |
Why?
|
| Endothelin-1 | 2 | 2004 | 313 | 0.060 |
Why?
|
| Reference Values | 5 | 2012 | 4982 | 0.060 |
Why?
|
| Double-Blind Method | 6 | 2015 | 12017 | 0.060 |
Why?
|
| Apolipoproteins B | 2 | 2013 | 373 | 0.060 |
Why?
|
| Platelet Activation | 2 | 2005 | 671 | 0.060 |
Why?
|
| Patient Selection | 2 | 2014 | 4214 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 2 | 2021 | 851 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2004 | 251 | 0.060 |
Why?
|
| Mental Recall | 1 | 2009 | 1205 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2002 | 1780 | 0.060 |
Why?
|
| Calcium Channel Blockers | 2 | 1996 | 689 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 2732 | 0.060 |
Why?
|
| Carbonated Beverages | 1 | 2004 | 214 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 231 | 0.050 |
Why?
|
| Self Report | 4 | 2016 | 3548 | 0.050 |
Why?
|
| Ontario | 2 | 2015 | 381 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2014 | 8297 | 0.050 |
Why?
|
| Coronary Restenosis | 1 | 2005 | 424 | 0.050 |
Why?
|
| Acculturation | 1 | 2004 | 181 | 0.050 |
Why?
|
| Hippocampus | 1 | 2015 | 3661 | 0.050 |
Why?
|
| Nova Scotia | 1 | 2002 | 34 | 0.050 |
Why?
|
| Work Schedule Tolerance | 1 | 2006 | 565 | 0.050 |
Why?
|
| Water Supply | 1 | 2004 | 214 | 0.050 |
Why?
|
| Factor VII | 4 | 2006 | 139 | 0.050 |
Why?
|
| Infant, Newborn | 5 | 2023 | 25575 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2009 | 6891 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2005 | 469 | 0.050 |
Why?
|
| Michigan | 1 | 2023 | 350 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2015 | 2187 | 0.050 |
Why?
|
| Vitamins | 1 | 2010 | 1608 | 0.050 |
Why?
|
| Follicular Phase | 1 | 2002 | 153 | 0.050 |
Why?
|
| Mexico | 1 | 2004 | 688 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2017 | 9144 | 0.050 |
Why?
|
| Hypoglycemic Agents | 2 | 2005 | 2866 | 0.050 |
Why?
|
| Blood Viscosity | 4 | 2005 | 124 | 0.050 |
Why?
|
| Neoplasms | 4 | 2017 | 21596 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2009 | 707 | 0.050 |
Why?
|
| Animals | 10 | 2015 | 168561 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2009 | 2751 | 0.050 |
Why?
|
| Health Education | 2 | 1999 | 1053 | 0.050 |
Why?
|
| Suicide | 1 | 2012 | 1475 | 0.050 |
Why?
|
| Antigens, Human Platelet | 1 | 2001 | 43 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2004 | 305 | 0.050 |
Why?
|
| Accident Prevention | 1 | 2001 | 78 | 0.050 |
Why?
|
| Premature Birth | 2 | 2012 | 1713 | 0.050 |
Why?
|
| Warfarin | 2 | 2008 | 1493 | 0.050 |
Why?
|
| Occupational Health Services | 1 | 2002 | 154 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7276 | 0.050 |
Why?
|
| Stents | 2 | 2005 | 3276 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 2885 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2010 | 1415 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 236 | 0.050 |
Why?
|
| Anticoagulants | 3 | 2021 | 4595 | 0.050 |
Why?
|
| Blood Pressure Monitors | 1 | 2020 | 33 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2012 | 1912 | 0.050 |
Why?
|
| Mathematical Computing | 2 | 2011 | 147 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2015 | 3738 | 0.050 |
Why?
|
| Data Collection | 4 | 2009 | 3339 | 0.050 |
Why?
|
| Emergencies | 1 | 2007 | 1164 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1998 | 1202 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1167 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 2749 | 0.050 |
Why?
|
| Athletic Injuries | 1 | 2010 | 1153 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2003 | 562 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2015 | 6191 | 0.040 |
Why?
|
| Depressive Disorder | 2 | 2005 | 3748 | 0.040 |
Why?
|
| Psychophysiology | 1 | 2000 | 135 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 2002 | 2536 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2002 | 298 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2022 | 433 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2002 | 253 | 0.040 |
Why?
|
| Quality of Life | 2 | 2019 | 12730 | 0.040 |
Why?
|
| Cholesterol, LDL | 3 | 2013 | 2354 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 2838 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 15494 | 0.040 |
Why?
|
| Safety | 1 | 2004 | 1185 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2001 | 909 | 0.040 |
Why?
|
| Cardiotonic Agents | 2 | 2012 | 535 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2015 | 4551 | 0.040 |
Why?
|
| Mammography | 1 | 2010 | 2474 | 0.040 |
Why?
|
| Disease Susceptibility | 2 | 2004 | 1780 | 0.040 |
Why?
|
| Apolipoproteins E | 4 | 2006 | 1438 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2019 | 86 | 0.040 |
Why?
|
| Models, Biological | 2 | 2012 | 9581 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2003 | 790 | 0.040 |
Why?
|
| Medical Records | 1 | 2004 | 1413 | 0.040 |
Why?
|
| Radial Artery | 1 | 2020 | 194 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 979 | 0.040 |
Why?
|
| Overweight | 1 | 2009 | 2366 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2000 | 319 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2000 | 623 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2001 | 641 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2001 | 1013 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2017 | 2303 | 0.040 |
Why?
|
| Length of Stay | 3 | 2021 | 6294 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 719 | 0.040 |
Why?
|
| Guatemala | 2 | 2009 | 142 | 0.040 |
Why?
|
| Genotype | 6 | 2011 | 12946 | 0.040 |
Why?
|
| Accidents | 1 | 1998 | 164 | 0.040 |
Why?
|
| Azithromycin | 1 | 2019 | 195 | 0.040 |
Why?
|
| Surface Properties | 2 | 2010 | 1182 | 0.040 |
Why?
|
| Blood Coagulation Factors | 1 | 2000 | 355 | 0.040 |
Why?
|
| Hypobetalipoproteinemias | 1 | 1997 | 11 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 1914 | 0.040 |
Why?
|
| Women | 1 | 1999 | 230 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 6483 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2003 | 882 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 4628 | 0.040 |
Why?
|
| Coronary Stenosis | 1 | 2003 | 834 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2012 | 4250 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2005 | 1155 | 0.040 |
Why?
|
| Chromium | 1 | 2017 | 123 | 0.040 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3679 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2000 | 415 | 0.040 |
Why?
|
| Sex | 1 | 1996 | 57 | 0.040 |
Why?
|
| Patient Admission | 1 | 2004 | 1380 | 0.030 |
Why?
|
| Adenosine Diphosphate | 3 | 2005 | 425 | 0.030 |
Why?
|
| Hip Joint | 1 | 2003 | 1002 | 0.030 |
Why?
|
| Dogs | 2 | 2015 | 3910 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 6754 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2016 | 165 | 0.030 |
Why?
|
| South Carolina | 1 | 2015 | 99 | 0.030 |
Why?
|
| Systole | 1 | 2018 | 956 | 0.030 |
Why?
|
| Peru | 1 | 2018 | 881 | 0.030 |
Why?
|
| Diastole | 1 | 2018 | 791 | 0.030 |
Why?
|
| Verapamil | 1 | 1996 | 244 | 0.030 |
Why?
|
| Austria | 1 | 1995 | 201 | 0.030 |
Why?
|
| Affect | 2 | 2014 | 1473 | 0.030 |
Why?
|
| Gases | 1 | 2016 | 197 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2003 | 1827 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2009 | 1155 | 0.030 |
Why?
|
| Iowa | 1 | 2015 | 100 | 0.030 |
Why?
|
| Cognition | 1 | 2012 | 6722 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2001 | 700 | 0.030 |
Why?
|
| Rabbits | 1 | 2001 | 4886 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 4933 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 425 | 0.030 |
Why?
|
| Catheterization | 1 | 2020 | 1468 | 0.030 |
Why?
|
| Work | 1 | 2015 | 191 | 0.030 |
Why?
|
| Central Nervous System Depressants | 1 | 2015 | 167 | 0.030 |
Why?
|
| Postmenopause | 3 | 1998 | 2461 | 0.030 |
Why?
|
| Manganese | 1 | 2017 | 408 | 0.030 |
Why?
|
| Pulse | 1 | 2014 | 229 | 0.030 |
Why?
|
| Child Welfare | 1 | 1998 | 523 | 0.030 |
Why?
|
| Hazardous Substances | 1 | 2015 | 149 | 0.030 |
Why?
|
| Fractures, Bone | 2 | 2004 | 1945 | 0.030 |
Why?
|
| Equipment Design | 1 | 2002 | 3582 | 0.030 |
Why?
|
| Organ Size | 1 | 2019 | 2253 | 0.030 |
Why?
|
| Employment | 1 | 2000 | 1124 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2019 | 2003 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6534 | 0.030 |
Why?
|
| Riboflavin | 1 | 2014 | 108 | 0.030 |
Why?
|
| Epinephrine | 3 | 2005 | 793 | 0.030 |
Why?
|
| Thoracic Surgery | 1 | 2020 | 713 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13019 | 0.030 |
Why?
|
| Leukocytes | 2 | 2014 | 2039 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 7901 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 571 | 0.030 |
Why?
|
| Vagus Nerve | 1 | 1996 | 437 | 0.030 |
Why?
|
| Integrin beta3 | 2 | 2005 | 122 | 0.030 |
Why?
|
| Heart Arrest | 1 | 2003 | 1469 | 0.030 |
Why?
|
| Echocardiography | 2 | 2019 | 5097 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2002 | 2161 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 689 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2019 | 1608 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1995 | 711 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2013 | 148 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2013 | 238 | 0.030 |
Why?
|
| Mitral Valve | 1 | 2021 | 1484 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 235 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 898 | 0.030 |
Why?
|
| Natriuretic Agents | 1 | 2011 | 25 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2001 | 1554 | 0.030 |
Why?
|
| Emergency Service, Hospital | 3 | 2011 | 7645 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 6171 | 0.030 |
Why?
|
| Blood Group Antigens | 1 | 2013 | 179 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2015 | 834 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2013 | 264 | 0.030 |
Why?
|
| Digoxin | 1 | 2012 | 250 | 0.030 |
Why?
|
| Dobutamine | 1 | 2011 | 123 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 1589 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2018 | 904 | 0.020 |
Why?
|
| Swine | 2 | 2012 | 5934 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 458 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2000 | 1368 | 0.020 |
Why?
|
| Estradiol | 1 | 1998 | 2021 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2013 | 281 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1996 | 1770 | 0.020 |
Why?
|
| Friction | 1 | 2010 | 59 | 0.020 |
Why?
|
| Renin | 2 | 2004 | 642 | 0.020 |
Why?
|
| Alu Elements | 1 | 2011 | 119 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2012 | 534 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2000 | 2050 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4328 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2011 | 153 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2012 | 302 | 0.020 |
Why?
|
| Psychology | 1 | 2012 | 355 | 0.020 |
Why?
|
| Hygiene | 1 | 2010 | 98 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2016 | 1200 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2013 | 936 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 638 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2019 | 40955 | 0.020 |
Why?
|
| Detergents | 1 | 2010 | 230 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2015 | 691 | 0.020 |
Why?
|
| Muscle Fatigue | 1 | 2010 | 82 | 0.020 |
Why?
|
| Public Health | 2 | 2015 | 2594 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 648 | 0.020 |
Why?
|
| Atrial Appendage | 1 | 2014 | 282 | 0.020 |
Why?
|
| Ohio | 1 | 2010 | 337 | 0.020 |
Why?
|
| Vitamin E | 1 | 2014 | 869 | 0.020 |
Why?
|
| Germany | 1 | 2012 | 860 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 628 | 0.020 |
Why?
|
| Value of Life | 2 | 2002 | 97 | 0.020 |
Why?
|
| Homes for the Aged | 1 | 2012 | 260 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 1792 | 0.020 |
Why?
|
| Health Occupations | 1 | 2011 | 223 | 0.020 |
Why?
|
| Phospholipids | 1 | 2013 | 781 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 1221 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 2043 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2002 | 3527 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2009 | 83 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2002 | 3203 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 338 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2009 | 141 | 0.020 |
Why?
|
| Environment Design | 1 | 2010 | 178 | 0.020 |
Why?
|
| Hirudins | 1 | 2009 | 182 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 1679 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2011 | 799 | 0.020 |
Why?
|
| Dementia | 1 | 2003 | 2501 | 0.020 |
Why?
|
| Inpatients | 1 | 2020 | 2495 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 159 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1997 | 1483 | 0.020 |
Why?
|
| Exercise Test | 2 | 2009 | 2075 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 1873 | 0.020 |
Why?
|
| Genome | 1 | 2017 | 1803 | 0.020 |
Why?
|
| Estrogens | 1 | 1995 | 1562 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 2414 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 2187 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 874 | 0.020 |
Why?
|
| Cholesterol, VLDL | 1 | 2007 | 65 | 0.020 |
Why?
|
| Folic Acid | 1 | 2014 | 1300 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2010 | 501 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 320 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2266 | 0.020 |
Why?
|
| Demography | 2 | 2001 | 1650 | 0.020 |
Why?
|
| Cooking | 1 | 2009 | 312 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2018 | 2055 | 0.020 |
Why?
|
| Missouri | 1 | 2006 | 116 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 2557 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2010 | 488 | 0.020 |
Why?
|
| Recurrence | 4 | 1999 | 8333 | 0.020 |
Why?
|
| Tissue Polypeptide Antigen | 1 | 2005 | 4 | 0.020 |
Why?
|
| Bone Development | 1 | 2009 | 483 | 0.020 |
Why?
|
| Beer | 1 | 2006 | 127 | 0.020 |
Why?
|
| Centrifugation | 1 | 2005 | 122 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2010 | 648 | 0.020 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 2005 | 56 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2005 | 70 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 934 | 0.020 |
Why?
|
| Wine | 1 | 2006 | 165 | 0.020 |
Why?
|
| Philadelphia | 1 | 2005 | 263 | 0.020 |
Why?
|
| Hyperventilation | 1 | 1984 | 81 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 2575 | 0.020 |
Why?
|
| Sodium Bicarbonate | 1 | 1984 | 62 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 4929 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2002 | 1679 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1984 | 110 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2004 | 377 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5062 | 0.010 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 430 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 2007 | 760 | 0.010 |
Why?
|
| Bicarbonates | 1 | 1984 | 313 | 0.010 |
Why?
|
| Tibia | 1 | 2009 | 1075 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1999 | 2027 | 0.010 |
Why?
|
| Glipizide | 1 | 2003 | 47 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 720 | 0.010 |
Why?
|
| Brain Infarction | 1 | 2005 | 296 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 1726 | 0.010 |
Why?
|
| Hypotonic Solutions | 1 | 2002 | 49 | 0.010 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2002 | 22 | 0.010 |
Why?
|
| P-Selectin | 1 | 2005 | 600 | 0.010 |
Why?
|
| Hemodialysis, Home | 1 | 2002 | 21 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2004 | 330 | 0.010 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2002 | 29 | 0.010 |
Why?
|
| Collagen | 2 | 2005 | 2684 | 0.010 |
Why?
|
| Censuses | 1 | 2004 | 200 | 0.010 |
Why?
|
| Direct Service Costs | 1 | 2002 | 62 | 0.010 |
Why?
|
| Glyburide | 1 | 2003 | 113 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 8925 | 0.010 |
Why?
|
| Longevity | 1 | 2010 | 1069 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 81045 | 0.010 |
Why?
|
| New Jersey | 1 | 2002 | 290 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 637 | 0.010 |
Why?
|
| Education | 1 | 2005 | 543 | 0.010 |
Why?
|
| Electrolytes | 1 | 2002 | 282 | 0.010 |
Why?
|
| Pain | 1 | 2017 | 4961 | 0.010 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2002 | 113 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 683 | 0.010 |
Why?
|
| Social Values | 1 | 2002 | 224 | 0.010 |
Why?
|
| Lidocaine | 1 | 1984 | 542 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2017 | 3306 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 2014 | 0.010 |
Why?
|
| Diet Records | 1 | 2003 | 425 | 0.010 |
Why?
|
| Menopause | 2 | 1999 | 1621 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2010 | 2680 | 0.010 |
Why?
|
| Critical Care | 1 | 2014 | 2640 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 918 | 0.010 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1981 | 147 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 2861 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 3123 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2015 | 3456 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2002 | 307 | 0.010 |
Why?
|
| Attention | 1 | 2010 | 2396 | 0.010 |
Why?
|
| Hearing Loss, Sudden | 1 | 1980 | 43 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2010 | 2924 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 6608 | 0.010 |
Why?
|
| Coitus | 1 | 2000 | 133 | 0.010 |
Why?
|
| Public Policy | 1 | 2004 | 572 | 0.010 |
Why?
|
| Atherectomy, Coronary | 1 | 1999 | 148 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1999 | 115 | 0.010 |
Why?
|
| Body Constitution | 1 | 1999 | 278 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 1360 | 0.010 |
Why?
|
| Family Health | 1 | 2004 | 1282 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2003 | 667 | 0.010 |
Why?
|
| Infant | 2 | 2012 | 35070 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2001 | 514 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 20774 | 0.010 |
Why?
|
| Veterans | 1 | 2012 | 2513 | 0.010 |
Why?
|
| Hawaii | 1 | 1998 | 104 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2009 | 2575 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3862 | 0.010 |
Why?
|
| Greece | 1 | 1998 | 344 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1997 | 23 | 0.010 |
Why?
|
| Retreatment | 1 | 1999 | 604 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1997 | 83 | 0.010 |
Why?
|
| Medicaid | 1 | 2011 | 2716 | 0.010 |
Why?
|
| Weight Loss | 1 | 2009 | 2604 | 0.010 |
Why?
|
| Documentation | 1 | 2004 | 865 | 0.010 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 1981 | 770 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2005 | 1423 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 35342 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 2 | 2002 | 5385 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 3760 | 0.010 |
Why?
|
| Epilepsy | 1 | 2012 | 3301 | 0.010 |
Why?
|
| Aldosterone | 1 | 2001 | 876 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1777 | 0.010 |
Why?
|
| Europe | 1 | 2003 | 3339 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2009 | 3584 | 0.010 |
Why?
|
| Progestins | 1 | 1998 | 303 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3839 | 0.010 |
Why?
|
| Femoral Artery | 1 | 2001 | 843 | 0.010 |
Why?
|
| Bone Density | 1 | 2009 | 3469 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 1369 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2003 | 1577 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2007 | 2896 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 2422 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2000 | 577 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2001 | 960 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 12220 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2000 | 876 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 6030 | 0.010 |
Why?
|
| Epitopes | 1 | 2001 | 2569 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3587 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 14554 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 1999 | 1203 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 1110 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2004 | 1884 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 1520 | 0.010 |
Why?
|
| Fasting | 1 | 2000 | 1589 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 3248 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2006 | 2346 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 12958 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2003 | 3418 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2003 | 1638 | 0.010 |
Why?
|
| Models, Economic | 1 | 1997 | 713 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1067 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1996 | 965 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2002 | 1582 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2005 | 17400 | 0.010 |
Why?
|
| Posture | 1 | 1996 | 958 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 9639 | 0.010 |
Why?
|
| Premenopause | 1 | 1995 | 1033 | 0.010 |
Why?
|
| Observer Variation | 1 | 1997 | 2593 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 6931 | 0.010 |
Why?
|
| Heart Defects, Congenital | 2 | 2004 | 4566 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 6974 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 1996 | 904 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2009 | 12164 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2005 | 4250 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2008 | 6587 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2001 | 3439 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 8621 | 0.000 |
Why?
|
| Forecasting | 1 | 1996 | 2948 | 0.000 |
Why?
|
| Cytokines | 1 | 2001 | 7317 | 0.000 |
Why?
|
| Audiometry, Speech | 1 | 1981 | 11 | 0.000 |
Why?
|
| Embolism | 1 | 1980 | 409 | 0.000 |
Why?
|
| HIV Infections | 1 | 2002 | 16678 | 0.000 |
Why?
|